These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15005255)

  • 21. [Sustained remission with allogeneic peripheral blood stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic crisis of imatinib-resistant CML].
    Narita T; Kayukawa S; Yoshida T; Kusumoto S; Kataoka T
    Rinsho Ketsueki; 2013 Mar; 54(3):279-83. PubMed ID: 23676643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
    Yujiri T; Sato Y; Tanizawa Y
    Int J Hematol; 2004 Jul; 80(1):67-9. PubMed ID: 15293571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.
    Altintas A; Cil T; Kilinc I; Kaplan MA; Ayyildiz O
    J Neurooncol; 2007 Aug; 84(1):103-5. PubMed ID: 17318411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
    Bujassoum S; Rifkind J; Lipton JH
    Leuk Lymphoma; 2004 Feb; 45(2):401-3. PubMed ID: 15101732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
    Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia.
    Al-Shehri A; Al-Seraihy A; Owaidah TM; Belgaumi AF
    Hematol Oncol Stem Cell Ther; 2010; 3(1):42-6. PubMed ID: 20231813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
    Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
    Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
    Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
    Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
    Wang Y; Wu D; Sun A; Jin Z; Qiu H; Miao M; Tang X; Fu Z
    Int J Hematol; 2008 Mar; 87(2):167-171. PubMed ID: 18288566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A; Siddiqui N
    Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low concentrations of STI571 in the cerebrospinal fluid: a case report.
    Petzer AL; Gunsilius E; Hayes M; Stockhammer G; Duba HC; Schneller F; Grünewald K; Poewe W; Gastl G
    Br J Haematol; 2002 Jun; 117(3):623-5. PubMed ID: 12028032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
    Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
    Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
    Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
    Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Successful induction of complete cytogenetic response with high-dose imatinib mesylate and subsequent allogeneic stem cell transplantation for CML blastic crisis].
    Sugiyama K; Usui N; Asai O; Saito T; Yano S; Okawa Y; Takahara S; Takei Y; Uno S; Dobashi N; Kobayashi M
    Rinsho Ketsueki; 2003 Jun; 44(6):386-90. PubMed ID: 12884817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.